Information Provided By: 
Fly News Breaks for February 1, 2019
FOLD
Feb 1, 2019 | 07:17 EDT
JPMorgan analyst Anupam Rama believes shares of Amicus Therapeutics are undervalued and that current levels provide an attractive long-term entry point. He raised his price target for the stock to $19 from $18 and keeps an Overweight rating on the name. The company is trading slightly above Galafold's standalone value, which implies that minimal credit is currently being ascribed to its Pompe program and gene therapy initiatives, Rama tells investors in a research note.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
